Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection

(2020) Seema A. Mehta Steinke et al.   Transplant Infectious Disease

Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice

(2019) Raymund R. Razonable et al.   CLINICAL TRANSPLANTATION

Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)

(2019) Per Ljungman et al.   LANCET INFECTIOUS DISEASES

Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation

(2019) Fareed Khawaja et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Effects of Maribavir on P‐Glycoprotein and CYP2D6 in Healthy Volunteers

(2019) Ivy H. Song et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation

(2019) Johan Maertens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection

(2019) Sunwen Chou et al.   ANTIVIRAL RESEARCH

Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence

(2019) Ghady Haidar et al.   JOURNAL OF INFECTIOUS DISEASES

Clinical and genotypic CMV drug resistance in HSCT recipients: a single center epidemiological and clinical data

(2018) Vejrazkova Eva et al.   BONE MARROW TRANSPLANTATION

Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: A single-center study

(2018) Brett Pierce et al.   Transplant Infectious Disease

The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation

(2018) Camille N. Kotton et al.   TRANSPLANTATION

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study

(2018) Genovefa A Papanicolaou et al.   CLINICAL INFECTIOUS DISEASES

Use of Cidofovir for Cytomegalovirus Disease Refractory to Ganciclovir in Solid Organ Recipients

(2017) Hugo Bonatti et al.   Surgical Infections

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

(2016) P. Teira et al.   BLOOD

How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients

(2016) F. El Chaer et al.   BLOOD

Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.

(2016) Per Ljungman et al.   CLINICAL INFECTIOUS DISEASES

Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis

(2016) E. Beam et al.   CLINICAL TRANSPLANTATION

Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection

(2016) Robin K. Avery et al.   TRANSPLANTATION

Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation

(2016) Enrico Maffini et al.   Expert Review of Hematology

Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality

(2015) J. Liu et al.   CLINICAL MICROBIOLOGY AND INFECTION

Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial

(2012) D. J. Winston et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

(2011) Francisco M Marty et al.   LANCET INFECTIOUS DISEASES

Maribavir and human cytomegalovirus—what happened in the clinical trials and why might the drug have failed?

(2011) Francisco M Marty et al.   Current Opinion in Virology

Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir

(2009) Mark N. Prichard   REVIEWS IN MEDICAL VIROLOGY

Viral Mimicry of Cdc2/Cyclin-Dependent Kinase 1 Mediates Disruption of Nuclear Lamina during Human Cytomegalovirus Nuclear Egress

(2009) Sofia Hamirally et al.   PLoS Pathogens